| Literature DB >> 33584496 |
Mattia Pozzato1,2, Emanuele Micaglio3, Chiara Starvaggi Cucuzza4, Alessandro Cagol4, Daniela Galimberti5, Daniela Calandrella6, Claudia Cinnante7, Carlo Pappone3, Monica Zanussi8, Giovanni Meola9,10, Elio Scarpini1,5, Nereo Bresolin1,2, Filippo Martinelli Boneschi1,2.
Abstract
Familial Mediterranean Fever (FMF) is a genetic autoinflammatory disease characterized by recurrent episodes of fever and serositis caused by mutations in the MEFV gene, while Multiple Sclerosis (MS) is an inflammatory demyelinating disease of the CNS with genetic and environmental etiology. The two diseases rarely occur in association with relevant implications for clinical management and drug choice. In this paper, we present the case of a 53-year-old male with an autosomal dominant FMF since childhood who presented acute paresthesia at the right part of the body. He performed a brain and spinal cord MRI, which showed multiple brain lesions and a gd-enhancing lesion in the cervical spinal cord, and then received a diagnosis of MS. He then started Interferonβ-1a which was effective but not tolerated and caused hepatotoxicity, and then shifted to Rituximab with 3-month clinical and neuroradiological efficacy.Entities:
Keywords: case report; familal mediterranean fever; hepatotoxicity; multiple sclerosis; rituximab
Year: 2021 PMID: 33584496 PMCID: PMC7874168 DOI: 10.3389/fneur.2020.591395
Source DB: PubMed Journal: Front Neurol ISSN: 1664-2295 Impact factor: 4.003